The immune checkpoint inhibitor (ICI) pembrolizumab is US FDA approved for treatment of
solid tumors with high tumor mutational burden (TMB-high; ≥10 variants/Mb). However, the …

Despite major advances in the management and high cure rates of childhood acute
lymphoblastic leukemia (ALL), patients still suffer from many drug-induced toxicities, sometimes …

Background Prevalence estimates for monoclonal gammopathy of undetermined significance
(MGUS) are based on predominantly White study populations screened by serum protein …

Multiple myeloma is a plasma cell malignancy almost always preceded by precursor
conditions, but low tumor burden of these early stages has hindered the study of their molecular …

Background Patients with precursors to multiple myeloma are dichotomised as having
monoclonal gammopathy of undetermined significance or smouldering multiple myeloma on the …

Monoclonal gammopathy of undetermined significance (MGUS) is a premalignant condition
of multiple myeloma with few known risk factors. The emergence of mass spectrometry (MS) …

LRRC4 is a novel relatively specific gene, which displays significant down-regulation in primary
brain tumor biopsies and has the potential to suppress brain tumor growth. In this study, …

Clonal hematopoiesis (CH) is associated with adverse outcomes in patients with non-Hodgkin
lymphoma (NHL) and multiple myeloma undergoing autologous stem cell transplantation. …

Endometriosis is a chronic condition primarily affecting young women of reproductive age.
Although some women with bowel endometriosis may be asymptomatic patients typically …

Background Multiple myeloma (MM) evolves from monoclonal gammopathy of undetermined
significance (MGUS), a clinically detectable but asymptomatic premalignant phase seen in …